A Comprehensive Monograph on Buspirone (DB00490): Pharmacology, Clinical Utility, and Therapeutic Context

Executive Summary

Buspirone is a novel anxiolytic agent belonging to the azaspirodecanedione class of drugs, distinguished by a pharmacological profile that is fundamentally different from traditional anxiolytics such as benzodiazepines and barbiturates. Its primary mechanism of action is centered on high-affinity partial agonism at serotonin 5-HT1A receptors, with secondary antagonist activity at dopamine D2 receptors. This unique mechanism underpins its clinical characteristics, most notably its efficacy in treating Generalized Anxiety Disorder (GAD) without inducing significant sedation, cognitive impairment, muscle relaxation, or anticonvulsant effects.

A hallmark of buspirone therapy is its delayed onset of anxiolytic action, typically requiring two to four weeks to achieve full therapeutic effect. This delay is a direct consequence of its pharmacodynamic mechanism, which relies on the gradual desensitization of presynaptic 5-HT1A autoreceptors to produce a net enhancement of serotonergic neurotransmission. This characteristic renders buspirone unsuitable for acute or "as-needed" management of anxiety but establishes its utility for chronic GAD.

The safety profile of buspirone is a key clinical advantage. It carries a very low risk for physical dependence, abuse, and withdrawal symptoms, making it a preferred therapeutic option for patients with GAD who have a history of substance use disorder or for whom the risks associated with long-term benzodiazepine use are a concern, such as the elderly. However, its use is not without risks. Buspirone is extensively metabolized by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme, making it highly susceptible to significant drug-drug and drug-food interactions. Co-administration with potent CYP3A4 inhibitors (e.g., itraconazole, erythromycin, grapefruit juice) can lead to dramatic increases in plasma concentrations and toxicity, while co-administration with inducers (e.g., rifampin, carbamazepine) can cause a loss of efficacy. Furthermore, there is a contraindicated risk of hypertensive crisis when used with monoamine oxidase inhibitors (MAOIs) and a potential for serotonin syndrome when combined with other serotonergic agents.

Clinically, buspirone is FDA-approved for GAD and is often positioned as a second-line agent after selective serotonin reuptake inhibitors (SSRIs) or as an adjunctive therapy for unipolar depression. Its selection requires careful consideration of the patient's clinical profile, concomitant medications, and the ability to adhere to a fixed-schedule regimen while awaiting its therapeutic effects. This monograph provides an exhaustive analysis of buspirone's chemistry, pharmacology, clinical applications, and therapeutic context to guide informed clinical decision-making.

Section 1: Introduction and Drug Profile

Historical Context and Development

Buspirone represents a significant departure from the anxiolytic therapies that preceded it. First synthesized in 1968 and subsequently patented in 1975, its developmental trajectory was initially aimed at the creation of a novel antipsychotic agent.[1] Early investigations revealed that while it was largely ineffective for treating psychosis, it possessed notable anxiolytic properties.[3] This historical origin is not merely a footnote; it is fundamental to understanding the drug's multifaceted receptor-binding profile. The residual affinity for and antagonism of dopamine receptors, a primary target for antipsychotic agents, is a legacy of this initial development pathway and explains some of its secondary pharmacological actions and rare side effects.[3]

Regulatory Approval and Market Introduction

Following the recognition of its anxiolytic potential, buspirone underwent clinical development for anxiety disorders. The U.S. Food and Drug Administration (FDA) granted its approval in 1986, introducing a new therapeutic class for the management of anxiety.[1] It was originally marketed under the brand name Buspar®.[1] Although the brand-name product has since been discontinued, generic buspirone is widely available and remains a prominent medication in clinical practice.[7] Its enduring use is evidenced by its ranking as the 54th most commonly prescribed medication in the United States in 2022, with over 12 million prescriptions filled.[4] This sustained market presence, long after the discontinuation of the brand-name product, indicates strong clinical and economic acceptance based on the drug's intrinsic therapeutic value and cost-effectiveness.

Chemical and Pharmacological Classification

Buspirone is chemically classified as an azaspiro compound and is the prototypical member of the azaspirodecanedione drug class.[1] Its structure and mechanism are chemically and pharmacologically unrelated to benzodiazepines, barbiturates, or other sedative/anxiolytic drugs.[1] This distinction is the cornerstone of its clinical profile. Unlike GABA-ergic agents, buspirone does not produce significant sedative, hypnotic, anticonvulsant, or muscle-relaxant effects.[1] This selective anxiolytic action without profound central nervous system (CNS) depression led to the coining of the term 'anxioselective' to describe its unique properties, setting it apart as a targeted therapy for the cognitive and emotional symptoms of anxiety.[1]

Section 2: Physicochemical Properties and Formulation

Chemical Identification and Structure

The precise identification of a pharmaceutical substance is critical for research, regulation, and clinical practice. Buspirone is a complex organic molecule with a distinct structure that dictates its pharmacological activity.

Its systematic International Union of Pure and Applied Chemistry (IUPAC) name is 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione.[1] The molecule's structure is characterized as an azaspiro compound, which contains a spirocyclic system involving a nitrogen atom. It is also a member of several chemical families, including pyrimidines, N-arylpiperazines, N-alkylpiperazines, and piperidones, reflecting its complex heterocyclic nature.[1] The core structure features an 8-azaspiro[4.5]decane-7,9-dione moiety. This is connected via a four-carbon butyl linker to a piperazine ring, which is itself substituted at the N4 position with a pyrimidin-2-yl group.[1]

The molecular formula for the free base form of buspirone is C21​H31​N5​O2​.[15] This corresponds to a molecular weight of approximately 385.50 g/mol.[15] For pharmaceutical use, it is typically formulated as a hydrochloride salt, which has a molecular weight of approximately 421.96 g/mol.[19] A consolidated list of key chemical identifiers is provided in Table 1 for cross-referencing across major scientific and regulatory databases.

Identifier	Value (Free Base unless specified)	Source(s)
Systematic (IUPAC) Name	8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione	1
CAS Number	36505-84-7 (free base) 33386-08-2 (HCl salt)	1
DrugBank ID	DB00490	1
ChEBI ID	CHEBI:3223	1
UNII (FDA GSRS)	TK65WKS8HL	1
Molecular Formula	C21​H31​N5​O2​	15
Molecular Weight	385.50 g/mol (free base) 421.96 g/mol (HCl salt)	18
SMILES	c1cnc(nc1)N2CCN(CC2)CCCCN3C(=O)CC4(CCCC4)CC3=O	1
InChIKey	QWCRAEMEVRGPNT-UHFFFAOYSA-N	1

Physical and Chemical Properties

Buspirone in its solid state is a white crystalline powder.[1] The melting point differs significantly between the free base and its hydrochloride salt, a common phenomenon in pharmaceutical chemistry. The hydrochloride salt has a reported melting point of 201.5-202.5 °C [1], whereas one source reports a melting point of 107 °C, which is likely for the free base form.[18]

Solubility is a key determinant of drug absorption. Buspirone free base is sparingly soluble in water, with a reported value of 0.588 g/L.[1] The conversion to the hydrochloride salt substantially improves its aqueous solubility, a deliberate formulation strategy to enhance dissolution and absorption following oral administration. The HCl salt is reported to be soluble at 10 mg/mL in water and is even more soluble in methanol (50 mg/mL).[19]

The partition coefficient (LogP) of buspirone is in the range of 2.3 to 2.63, indicating moderate lipophilicity.[1] This property allows it to readily cross the blood-brain barrier to exert its effects on the central nervous system. As a basic compound containing multiple nitrogen atoms, buspirone has a basic pKa of 7.6 [1], meaning it will be significantly ionized at physiological pH, which also influences its absorption and distribution characteristics.

Commercial Formulations and Related Impurities

Buspirone is commercially available for oral administration in tablet form. Standard strengths include 5 mg, 7.5 mg, 10 mg, 15 mg, and 30 mg, providing a range of dosing options for clinicians.[23] A notable feature of the 15 mg and 30 mg tablets is that they are manufactured as "Dividose®" tablets, which are scored to be broken into two or three equal parts.[23] This design is not merely for convenience; it is a critical formulation feature that directly facilitates the slow, gradual dose titration recommended in clinical guidelines. This allows for precise dose adjustments in increments of 5 mg, 7.5 mg, 10 mg, or 15 mg, enabling clinicians to carefully manage side effects and optimize the therapeutic response for individual patients.[23]

For the purposes of quality control and pharmaceutical analysis, various reference standards for buspirone-related impurities are available. These include compounds formed during synthesis or degradation, such as Buspirone N-Oxide Oxalate and 8-(4-Chlorobutyl)-8-azaspiro[4.5]decane-7,9-dione.[16] The control of such impurities is a critical aspect of drug manufacturing and regulatory compliance to ensure the safety and purity of the final drug product.

Section 3: Pharmacodynamics: Mechanism of Action

The anxiolytic effect of buspirone arises from a complex and unique mechanism of action that is fundamentally different from that of benzodiazepines and selective serotonin reuptake inhibitors (SSRIs). Its pharmacodynamic profile is characterized by high-affinity interactions with specific serotonin receptors, coupled with secondary effects on dopamine receptor systems.

Primary Serotonergic Activity: The 5-HT1A Receptor Partial Agonism

The principal mechanism of action of buspirone is its activity as a high-affinity partial agonist at serotonin 5-HT1A receptors.[4] This interaction is not uniform across all 5-HT1A receptor locations. Buspirone functions as a full agonist at presynaptic 5-HT1A autoreceptors, which are primarily located on the soma and dendrites of serotonergic neurons in the dorsal raphe nucleus. In contrast, it acts as a partial agonist at postsynaptic 5-HT1A receptors, which are abundant in limbic system structures such as the hippocampus and cortex.[4]

This distinction is crucial. The presynaptic autoreceptors function as a negative feedback mechanism, or a "brake," on the serotonergic system. When activated, they inhibit the firing of the neuron, thereby reducing the synthesis and release of serotonin into the synapse. The postsynaptic receptors, on the other hand, mediate the downstream effects of serotonin in target brain regions. Buspirone also demonstrates some affinity for other serotonin receptor subtypes, including 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7, where it is thought to function as an antagonist, although these interactions are considered secondary to its primary 5-HT1A-mediated effects.[4]

Secondary Receptor Interactions: Dopaminergic and Adrenergic Systems

Reflecting its developmental history as a potential antipsychotic, buspirone also interacts with dopamine receptors. It functions as an antagonist at dopamine D2 receptors, exhibiting a preferential affinity for the inhibitory presynaptic D2 autoreceptors at lower, clinically relevant doses.[4] This action can lead to an increase in dopaminergic neurotransmission. At higher doses, buspirone also blocks postsynaptic D2 receptors, which can produce antidopaminergic effects.[4] It possesses an even higher affinity for dopamine D3 and D4 receptors, where it also acts as an antagonist.[4] These dopaminergic effects are believed to be less central to its anxiolytic action than its serotonergic activity but may contribute to its overall clinical profile and account for rare extrapyramidal side effects.

Additionally, some evidence suggests that buspirone may act as a partial agonist at alpha-1 adrenergic receptors.[21] It also exhibits weak antagonistic properties at muscarinic acetylcholine receptors, which may account for some of its minor anticholinergic side effects, such as dry mouth.[18]

Neurobiological Basis for the Delayed Onset of Anxiolytic Action

A defining clinical characteristic of buspirone is its delayed onset of therapeutic action, which typically requires two to four weeks to become fully manifest.[4] This delay is a direct and predictable consequence of its unique pharmacodynamic mechanism and is not observed with fast-acting anxiolytics like benzodiazepines. The process involves a time-dependent neuroadaptation within the serotonergic system.

The sequence of events is as follows: Upon initial administration, buspirone's potent full agonist activity at presynaptic 5-HT1A autoreceptors dominates. This leads to the activation of the neuronal "brake," causing an immediate inhibition of serotonin synthesis and release from dorsal raphe neurons.[4] This initial reduction in serotonergic output is not anxiolytic and may explain the lack of immediate therapeutic benefit.

However, with continued, chronic administration over several weeks, the brain's homeostatic mechanisms respond to this persistent autoreceptor stimulation. This response involves the gradual desensitization and downregulation of the presynaptic 5-HT1A autoreceptors themselves.[10] As these autoreceptors become less sensitive, their inhibitory influence on the serotonergic neurons wanes. This process effectively "releases the brake" on the system, leading to a disinhibition of the serotonergic neurons. The ultimate result is a restoration and net enhancement of the serotonergic firing rate and an increase in the release of serotonin in key projection areas like the amygdala and cortex. This heightened serotonergic tone is believed to be the neurobiological substrate for buspirone's therapeutic anxiolytic effect.[10] This multi-week neuroadaptive process explains why the drug is ineffective for "as-needed" or acute panic situations and underscores the critical need for patient education to ensure adherence during the initial period of non-response.

Mechanistic Distinction from GABAergic and Reuptake-Inhibiting Agents

Buspirone's mechanism of action sets it apart from the two other major classes of anxiolytic medications.

Unlike benzodiazepines, buspirone has no affinity for and does not modulate gamma-aminobutyric acid (GABA) receptors, the primary inhibitory neurotransmitter system in the brain.[5] The potentiation of GABA-A receptor function is the mechanism by which benzodiazepines produce their rapid anxiolytic, sedative, hypnotic, and muscle-relaxant effects. Buspirone's lack of interaction with this system is the fundamental reason it is devoid of these properties and, most importantly, why it does not carry the significant risk of physical dependence, tolerance, and withdrawal associated with benzodiazepines.[1]

Unlike SSRIs, which exert their effect indirectly by blocking the presynaptic serotonin transporter (SERT) to increase the dwell time and concentration of serotonin in the synaptic cleft, buspirone acts directly on the serotonin receptors themselves.[18] While the end goal of both drug classes is to modulate serotonergic neurotransmission, these distinct mechanisms—direct receptor modulation versus indirect reuptake inhibition—result in different side effect profiles, clinical applications, and timelines for therapeutic effect.

Section 4: Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The clinical use of buspirone, including its dosing schedule, potential for drug interactions, and application in specific patient populations, is profoundly influenced by its pharmacokinetic profile. Its journey through the body is characterized by rapid absorption, extensive first-pass metabolism, a short half-life, and reliance on the CYP3A4 enzyme system.

Absorption and Bioavailability: The Impact of First-Pass Metabolism and Food

Following oral administration, buspirone is absorbed rapidly from the gastrointestinal tract.[10] However, its journey to the systemic circulation is significantly impeded by extensive first-pass metabolism. As the absorbed drug passes through the liver for the first time, a large fraction is metabolized before it can reach the rest of the body. This process results in a low and somewhat variable systemic bioavailability, estimated to be only around 4% to 5% of the administered oral dose.[10]

A clinically significant food-drug interaction affects this process. While the co-administration of buspirone with food can decrease the rate of its absorption, it paradoxically leads to a net increase in its overall bioavailability.[10] This occurs because food also reduces the extent of the first-pass metabolism in the liver, allowing a larger proportion of the parent drug to escape into the systemic circulation. This results in an increase in both the peak plasma concentration (Cmax) and the total drug exposure (Area Under the Curve, AUC).[10] This interaction underscores the clinical recommendation to administer buspirone in a consistent manner relative to meals to ensure predictable and stable plasma concentrations. After a single oral dose, peak plasma concentrations are typically reached within 40 to 90 minutes (Tmax).[10]

Distribution, Volume, and Plasma Protein Binding

Once in the systemic circulation, buspirone distributes extensively into body tissues. This is reflected by its large apparent volume of distribution (Vd) of 5.3 L/kg.[10] This value, being much larger than the volume of total body water, indicates that the drug is not confined to the bloodstream and partitions readily into peripheral tissues, including the central nervous system where it exerts its effects.

In the plasma, buspirone is highly bound to proteins, with estimates ranging from 86% to 95%.[10] It primarily binds to serum albumin and, to a lesser extent, alpha-1-acid glycoprotein.[10] While high, this protein binding is only clinically significant if displaced by other highly bound drugs, a scenario that is relatively uncommon but possible.

Metabolic Pathways: The Central Role of CYP3A4 and the Active Metabolite 1-PP

Buspirone is almost completely metabolized before excretion, with the liver being the primary site of this transformation. The metabolic process is predominantly one of oxidation, mediated almost exclusively by the cytochrome P450 3A4 (CYP3A4) isoenzyme.[10] This heavy reliance on a single metabolic pathway makes buspirone highly vulnerable to drug interactions involving inhibitors or inducers of CYP3A4.

The metabolism of buspirone yields several hydroxylated derivatives. The most significant of these is 1-(2-pyrimidinyl)piperazine, commonly abbreviated as 1-PP.[5] This metabolite is not inert; it is pharmacologically active, possessing approximately one-quarter of the activity of the parent compound.[10] Furthermore, 1-PP has a longer elimination half-life than buspirone itself. This may contribute to the overall therapeutic effect and help to "smooth out" the pharmacological activity between doses, which is relevant given the short half-life of the parent drug. More recent preclinical data also suggest that another metabolite, 6-hydroxybuspirone (6-OH-buspirone), is also active and likely contributes to the clinical efficacy of buspirone.[33]

Elimination, Half-Life, and Systemic Clearance

The elimination of buspirone is characterized by a short half-life and high clearance. The elimination half-life (t1/2​) of unchanged buspirone is brief, averaging between 2 and 3 hours.[10] The active metabolite, 1-PP, persists longer in the body, with a mean elimination half-life of approximately 6 hours.[14]

Excretion of the drug occurs primarily in the form of its metabolites. Following a radiolabeled dose, approximately 29% to 63% is recovered in the urine within 24 hours, with another 18% to 38% eliminated via fecal excretion.[10] The high systemic clearance rate of 1.7 L/h/kg is consistent with the drug's extensive first-pass metabolism and rapid elimination from the body.[10]

Parameter	Value / Description	Clinical Implication	Source(s)
Bioavailability (F)	~5%	Low due to high first-pass metabolism. Increases with food.	10
Time to Peak (Tmax)	40–90 minutes	Rapid absorption from the GI tract.	10
Plasma Protein Binding	~95%	Highly bound, mainly to albumin.	14
Volume of Distribution (Vd)	5.3 L/kg	Extensive distribution into body tissues, including the CNS.	10
Metabolism	Hepatic, primarily via CYP3A4	High potential for drug-drug interactions.	10
Active Metabolite	1-pyrimidinylpiperazine (1-PP)	Contributes to overall pharmacological effect; has a longer half-life.	10
Elimination Half-life (t1/2​)	2–3 hours (Buspirone) ~6 hours (1-PP)	Short duration of parent drug requires multiple daily doses.	10
Excretion	~60% Renal, ~40% Fecal (as metabolites)	Elimination depends on hepatic metabolism, not direct renal clearance of parent drug.	10

Pharmacokinetics in Special Populations

The pharmacokinetic profile of buspirone can be significantly altered in patients with organ dysfunction, necessitating careful dose consideration.

• Hepatic Impairment: This is the most critical consideration. Due to buspirone's near-complete reliance on hepatic first-pass metabolism, liver dysfunction can lead to a dramatic increase in drug exposure. In patients with hepatic cirrhosis, a single dose of buspirone resulted in a 13-fold increase in AUC and a 16-fold increase in Cmax compared to healthy individuals.[31] This massive increase in exposure elevates the risk of toxicity substantially. Consequently, buspirone use is not recommended in patients with severe hepatic impairment, and significant dose reductions are required for those with mild to moderate impairment.[3]
• Renal Impairment: While metabolism is hepatic, the resulting metabolites are cleared by the kidneys. In patients with renal impairment, the clearance of these metabolites is reduced, which can lead to their accumulation. Therefore, buspirone should be used with caution and at reduced doses in patients with renal disease. Its use in patients with severe renal impairment (anuria) is not recommended.[24]
• Geriatric Patients: While age alone does not typically necessitate a dosage adjustment, elderly patients may have reduced hepatic or renal function, which could decrease buspirone clearance.[23] Caution is therefore warranted. However, buspirone is often considered a safer alternative to benzodiazepines in the elderly due to its more favorable side effect profile, particularly regarding sedation and cognitive impairment.[12]

Section 5: Clinical Efficacy and Therapeutic Applications

Buspirone occupies a specific niche within the psychopharmacological armamentarium, defined by its targeted efficacy for Generalized Anxiety Disorder (GAD) and its growing role in several off-label applications. Its clinical profile can be characterized as that of a "specialist" agent, excelling in particular scenarios, rather than a "generalist" with broad-spectrum activity across multiple psychiatric conditions.

FDA-Approved Indication: Management of Generalized Anxiety Disorder (GAD)

The primary, FDA-approved indication for buspirone is the management of Generalized Anxiety Disorder (GAD) and the short-term relief of the symptoms of anxiety.[1] It is important to note that this indication does not extend to the normal anxiety or tension associated with the stress of everyday life.[23]

Multiple controlled clinical trials have established the efficacy of buspirone in GAD, demonstrating a therapeutic effect that is comparable to that of standard benzodiazepine therapies, including diazepam, alprazolam, lorazepam, and clorazepate.[4] However, buspirone appears to have a differential effect on the symptom clusters of GAD. Limited evidence suggests that it may be more effective for addressing the cognitive and interpersonal symptoms, such as worry, apprehension, anger, and hostility, whereas benzodiazepines may be more potent in alleviating the somatic symptoms of anxiety, such as muscle tension and autonomic hyperactivity.[23] Buspirone has also been shown to effectively reduce symptoms of anxiety in patients who have coexisting depressive symptoms.[23]

A crucial factor influencing its efficacy is a patient's prior medication history. Studies have shown that the anxiolytic response to buspirone may be diminished or less satisfactory in patients who have been previously treated with benzodiazepines.[3] This phenomenon may be attributable to several factors, including the patient's expectation for the rapid, potent relief provided by GABAergic agents, or the unmasking of underlying benzodiazepine withdrawal symptoms, which buspirone is not effective in treating.[12]

Off-Label Applications: A Critical Review of Evidence

Beyond its approved indication, buspirone is utilized in several off-label clinical scenarios, often as an adjunctive or second-line therapy.

• Augmentation for Unipolar Depression: One of the most common off-label uses is as an augmentation agent for unipolar depression in patients who have had an inadequate response to monotherapy with an SSRI.[1] The large-scale Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial provided significant evidence supporting this strategy, demonstrating that adding buspirone to an existing SSRI regimen can be an effective approach for treatment-resistant depression.[3]
• SSRI-Induced Sexual Dysfunction: Buspirone has demonstrated efficacy in mitigating one of the most common and distressing side effects of SSRI antidepressants: sexual dysfunction.[3] Its 5-HT1A agonist properties are thought to counteract the negative effects of broader serotonin enhancement on sexual function, making it a useful adjunctive treatment for patients experiencing these side effects.
• Other Investigational Uses: The unique pharmacological profile of buspirone has led to its investigation in a wide range of other conditions. There is some evidence for its use in treating hypoactive sexual desire disorder (HSDD) in women [4] and for managing antidepressant-induced bruxism (teeth grinding).[4] Due to its effects on the dopamine system, it has been explored for attenuating the side effects of Parkinson's disease therapies, such as levodopa-induced dyskinesia.[3] Other areas of investigation include the management of behavioral disturbances following brain injury or associated with dementia and Alzheimer's disease, pediatric anxiety disorders, and smoking cessation.[3]

Conditions with Limited or Unproven Efficacy

It is equally important to recognize the conditions for which buspirone is not considered an effective treatment. Despite its efficacy in GAD, it is not known to be effective for other major anxiety disorders, such as panic disorder, social anxiety disorder, or obsessive-compulsive disorder.[4] Its delayed onset of action makes it unsuitable for any condition requiring rapid anxiolysis.

Crucially, buspirone is not effective for treating the withdrawal syndromes associated with the discontinuation of benzodiazepines, barbiturates, or alcohol.[4] Patients must be gradually tapered off these CNS depressants before initiating buspirone, as it will not prevent or alleviate withdrawal symptoms.

Current and Future Research Directions

Research into buspirone and its applications is ongoing. A Phase III clinical trial, identified as NCT06243614, is currently recruiting participants to evaluate a new capsule formulation containing buspirone (Buagafuran) for the treatment of GAD, indicating continued interest in optimizing its delivery and efficacy.[22] Furthermore, novel combination therapies are being explored. The potential use of buspirone in conjunction with melatonin is being investigated for its effects on depression and cognitive impairment, with a proposed mechanism involving the promotion of neurogenesis.[1] These research avenues suggest that the full therapeutic potential of buspirone may still be unfolding.

Section 6: Dosing, Administration, and Clinical Management

The successful implementation of buspirone therapy requires a methodical approach to dosing and administration, coupled with comprehensive patient counseling to manage expectations and optimize adherence. The guidelines for its use are directly informed by its pharmacokinetic and pharmacodynamic properties.

Recommended Dosing Regimens, Titration Schedules, and Maximum Dosages

• Adult Dosing:
• Initial Dose: The usual starting dosage for adults with GAD is 15 mg per day, typically administered as 7.5 mg twice daily or 5 mg three times daily.[23] Some guidelines suggest a range of 10-15 mg per day in two or three divided doses to begin therapy.[23]
• Dose Titration: To balance efficacy with tolerability, the dose should be increased gradually. The recommended titration schedule is an increment of 5 mg per day every two to four days, based on the patient's clinical response.[8] This slow upward titration helps the patient acclimate to the medication and minimizes initial side effects like dizziness.
• Maintenance Dose: The majority of patients achieve a therapeutic response at a maintenance dosage between 15 mg and 30 mg per day, administered in divided doses.[23] The usual effective daily dose range is 20 to 30 mg per day.[31]
• Maximum Dose: The total daily dosage should not exceed 60 mg.[23]
• Pediatric Dosing (Off-label):
• The safety and efficacy of buspirone in pediatric populations have not been formally established. However, it is used off-label for anxiety in children and adolescents. Dosing regimens from clinical studies suggest starting with 2.5-5 mg per day for pre-adolescents and 5-10 mg per day for adolescents, with gradual titration up to a maximum daily dose of 20-60 mg, depending on age and clinical response.[3]

Administration Guidelines and Consistency Relative to Food Intake

Buspirone is administered orally in tablet form.[4] A critical aspect of its administration relates to its interaction with food. As established by pharmacokinetic studies, food significantly increases the bioavailability of buspirone by reducing its extensive first-pass metabolism.[10] Taking the drug with food one day and on an empty stomach the next would result in substantial fluctuations in plasma concentrations, potentially leading to inconsistent clinical effects or an increased incidence of side effects.

To mitigate this variability and ensure a more stable and predictable therapeutic response, patients must be instructed to take buspirone in a consistent manner relative to food. This means they should choose to take it either always with food or always without food for every dose.[8] This practical instruction is a direct clinical application of a key pharmacokinetic principle of the drug.

Essential Patient Counseling Points for Optimizing Adherence and Outcomes

Effective patient education is paramount for the successful use of buspirone, particularly due to its unique pharmacological profile. The following points should be emphasized:

• Delayed Onset of Action: Patients must be clearly informed that buspirone is not a fast-acting medication. The anxiolytic effects may not become apparent for two to four weeks, and the full therapeutic benefit may take up to six weeks to develop.[4] This manages expectations and prevents premature discontinuation due to a perceived lack of efficacy. It must be stressed that it is not a "rescue" or "as-needed" (PRN) medication for acute anxiety or panic attacks.[26]
• Continuous Adherence: The importance of taking the medication every day as prescribed, on a fixed schedule, must be reinforced. The therapeutic effect depends on the chronic administration needed to drive neuroadaptive changes.[26]
• Management of Side Effects: Patients should be warned about common initial side effects, particularly dizziness, lightheadedness, and nausea, and reassured that these often diminish with continued use.[4] They should be advised to exercise caution when driving, operating heavy machinery, or performing other tasks requiring alertness until they are familiar with how the drug affects them.[8]
• Alcohol and CNS Depressants: Patients should be strongly advised to avoid or limit the consumption of alcoholic beverages, as alcohol can potentiate the drowsiness and dizziness caused by buspirone.[8] Similar caution applies to other CNS depressants.
• Consistency with Food: The instruction to take the medication consistently with or without food should be explicitly communicated and explained to ensure stable drug levels.[8]

Section 7: Safety Profile, Adverse Events, and Contraindications

The safety profile of buspirone is one of its most defining features, offering significant advantages over older anxiolytic classes, particularly regarding dependence and sedation. However, it is not without risks, and a thorough understanding of its potential adverse effects and contraindications is essential for safe prescribing. The side effect profile is a direct reflection of its receptor-binding activities.

Common and Infrequent Adverse Drug Reactions

The most frequently reported adverse effects are generally mild to moderate in severity and often transient, diminishing as the body adapts to the medication.

• Most Common Adverse Effects: The side effects that occur significantly more frequently with buspirone than with placebo are primarily related to its effects on the central nervous system. These include dizziness (reported in 9-12% of patients), nausea (8%), headache (6-7%), nervousness (4-5%), lightheadedness (4%), and excitement or restlessness.[4] These effects are likely linked to its primary 5-HT1A agonist activity.
• Drowsiness: While drowsiness is reported in approximately 9-10% of patients, clinical trial data show that this incidence rate is not significantly different from that observed in patients receiving placebo.[40] This lack of significant sedation is a key differentiating feature compared to benzodiazepines, where drowsiness is a prominent and dose-limiting side effect.[40]
• Less Common Adverse Effects: Other reported side effects include blurred vision, dry mouth (a possible anticholinergic effect), fatigue or weakness, sleep disturbances such as insomnia or vivid dreams, and various gastrointestinal complaints like diarrhea or constipation.[13]

System Organ Class	Common (1% to 10%)	Uncommon (0.1% to 1%)	Rare/Very Rare (<0.1%)
Nervous System	Dizziness, headache, drowsiness, nervousness, lightheadedness, excitement, sleep disturbance	Decreased concentration, confusion, depersonalization, numbness/paresthesias, incoordination, tremor	Serotonin syndrome, seizures, extrapyramidal symptoms (akathisia, dystonia, parkinsonism), amnesia, ataxia
Gastrointestinal	Nausea, dry mouth, abdominal/gastric distress, diarrhea, constipation	Increased appetite, anorexia, salivation, rectal bleeding, flatulence	Burning of the tongue
Cardiovascular	Tachycardia/palpitations, chest pain	Hypotension, hypertension, syncope	Congestive heart failure, myocardial infarction, bradycardia, cardiomyopathy
Psychiatric	Dream disturbances	Dysphoria, fearfulness, loss of interest, hallucinations, suicidal ideation, libido changes	Claustrophobia, psychosis, emotional lability
Dermatologic	Rash, sweating/clamminess	Pruritus, flushing, easy bruising, dry skin, hair loss	Acne, urticaria, ecchymosis
Musculoskeletal	Musculoskeletal aches/pains	Muscle cramps, muscle spasms, arthralgias	Muscle weakness
Ocular	Blurred vision	Eye redness and itching, conjunctivitis, eye pain	Visual changes (including tunnel vision)
Other	Fatigue/weakness, tinnitus, sore throat, nasal congestion	Altered taste/smell, fever, malaise	Alcohol abuse, loss of voice, hiccoughs
	4

Serious Adverse Events

Although rare, buspirone is associated with several potentially serious adverse events that require immediate medical attention.

• Serotonin Syndrome: As a serotonergic agent, buspirone carries a risk of inducing serotonin syndrome, a potentially life-threatening condition characterized by a triad of cognitive (agitation, confusion), autonomic (tachycardia, fever, sweating), and neuromuscular (tremor, muscle rigidity, myoclonus) symptoms.[4] The risk is substantially elevated when buspirone is co-administered with other serotonergic drugs.
• Extrapyramidal Symptoms (EPS): Its antagonist activity at dopamine D2 receptors, a legacy of its development as an antipsychotic, can rarely lead to EPS. There have been postmarketing reports of akathisia (a state of inner restlessness), dystonic reactions, parkinsonism, and tardive dyskinesia.[39]
• Seizures: Seizures have been reported rarely, and caution is advised in patients with a history of seizure disorders.[4]

Absolute and Relative Contraindications and Clinical Precautions

• Absolute Contraindication: The most critical contraindication is the concomitant use of buspirone with a Monoamine Oxidase Inhibitor (MAOI) or use within 14 days of discontinuing an MAOI. This combination can precipitate a hypertensive crisis, characterized by a rapid and dangerous increase in blood pressure.[13]
• Precautions and Relative Contraindications:
• Severe Organ Impairment: Buspirone is not recommended for use in patients with severe hepatic or severe renal impairment due to the risk of dramatically increased drug exposure and accumulation of metabolites, respectively.[24]
• CNS Depression: Although less sedating than other anxiolytics, it can still impair judgment and motor skills. Patients should be cautioned about operating hazardous machinery, and the effects can be additive with other CNS depressants, including alcohol.[8]
• Pregnancy and Lactation: Its use in pregnancy has not been well studied, though it appears to be relatively safe. It is unknown if buspirone is excreted in human breast milk, so caution is advised during breastfeeding.[4]

Overdose Profile and Management

In cases of overdose, the most common symptoms are severe drowsiness, dizziness or lightheadedness, nausea and vomiting, and miosis (constricted, pinpoint pupils).[26] Overdose with buspirone alone is generally not considered life-threatening. There is no specific antidote, and management is supportive, consisting of gastric lavage if appropriate and general symptomatic and supportive measures.[26]

Long-Term Safety and Analysis of Dependence and Withdrawal Potential

A cornerstone of buspirone's safety profile is its remarkably low potential for abuse, physical dependence, and withdrawal.[4] It is not classified as a controlled substance.[44] This stands in stark contrast to benzodiazepines, where dependence is a major clinical concern. Studies involving long-term administration (up to one year) have not revealed any significant ill effects or loss of efficacy.[13] While a formal withdrawal syndrome is not characteristic of buspirone, gradual tapering upon discontinuation is still generally recommended as a matter of good clinical practice to avoid any potential rebound of underlying anxiety symptoms.[34]

Section 8: Significant Drug and Food Interactions

The clinical safety and efficacy of buspirone are heavily influenced by its potential for significant interactions with other drugs, supplements, and certain foods. These interactions are primarily driven by its reliance on the CYP3A4 metabolic pathway and its own serotonergic activity. A thorough review of a patient's concomitant medications and diet is therefore a mandatory step before initiating therapy.

Contraindicated Combinations: The Hypertensive Risk with Monoamine Oxidase Inhibitors (MAOIs)

The most severe interaction involves the co-administration of buspirone with Monoamine Oxidase Inhibitors (MAOIs). This combination is strictly contraindicated. There have been multiple reports of the occurrence of a hypertensive crisis—a rapid and dangerous elevation of blood pressure—when buspirone is added to a therapeutic regimen that includes an MAOI.[13] This includes irreversible MAOIs like phenelzine and tranylcypromine, as well as the reversible MAOI linezolid. To avoid this risk, a washout period of at least 14 days is required between the discontinuation of an MAOI and the initiation of buspirone, and vice versa.[26]

Pharmacokinetic Interactions: The Impact of CYP3A4 Inducers and Inhibitors

Buspirone's extensive metabolism by the CYP3A4 isoenzyme makes it highly susceptible to pharmacokinetic interactions with substances that inhibit or induce this enzyme. These interactions are not subtle and can dramatically alter buspirone exposure, leading to either toxicity or therapeutic failure.

• CYP3A4 Inhibitors: Potent inhibitors of CYP3A4 block the metabolism of buspirone, leading to a substantial increase in its plasma concentration. This effect is multiplicative, not additive, because it primarily affects the drug's first-pass metabolism.
• Examples: The antifungal agent itraconazole has been shown to increase the Cmax of buspirone 13-fold and the AUC 19-fold. The antibiotic erythromycin increased Cmax 5-fold and AUC 6-fold. Other potent inhibitors include nefazodone, and the calcium channel blockers diltiazem and verapamil.[31]
• Food Interaction: Large quantities of grapefruit juice are also a well-known potent inhibitor of intestinal CYP3A4 and can significantly increase buspirone levels.[26]
• Clinical Management: When co-administration with a potent CYP3A4 inhibitor is necessary, the initial dose of buspirone should be significantly reduced (e.g., to 2.5 mg once or twice daily), and the patient should be monitored closely for adverse effects.[23]
• CYP3A4 Inducers: Potent inducers of CYP3A4 have the opposite effect. They accelerate the metabolism of buspirone, leading to a profound decrease in its plasma concentration and a potential loss of anxiolytic efficacy.
• Examples: The antibiotic rifampin has been shown to decrease buspirone's Cmax by 84% and its AUC by 90%.[31] Other potent inducers include the anticonvulsants carbamazepine and phenytoin, and the herbal supplement St. John's Wort.[24]
• Clinical Management: If a patient on a stable dose of buspirone must start a potent CYP3A4 inducer, the anxiolytic effect may be lost. An increase in the buspirone dose may be required, or the combination should be avoided if possible.

Pharmacodynamic Interactions: Additive Risks with Other Serotonergic Agents and CNS Depressants

• Other Serotonergic Drugs: Due to its own effects on the serotonin system, combining buspirone with other serotonergic agents increases the cumulative risk of developing serotonin syndrome. This includes drugs such as SSRIs (e.g., fluoxetine, sertraline), SNRIs (e.g., venlafaxine, duloxetine), tricyclic antidepressants, triptans, and trazodone.[4] While these combinations are common in clinical practice (e.g., for augmentation), they require caution and careful monitoring for symptoms of serotonin toxicity.
• CNS Depressants: Although buspirone itself is not a potent CNS depressant, its mild sedative and dizzying effects can be additive with those of other CNS depressants. This includes alcohol, opioids, benzodiazepines, and certain antihistamines.[8] Patients should be counseled to avoid alcohol and to use caution when taking other medications that can cause drowsiness.

Interacting Agent/Class	Example(s)	Mechanism & Clinical Effect	Management Recommendation
Monoamine Oxidase Inhibitors (MAOIs)	Phenelzine, Tranylcypromine, Linezolid	Pharmacodynamic; Unknown mechanism leads to risk of severe hypertensive crisis.	Contraindicated. Allow a 14-day washout period between agents.
Potent CYP3A4 Inhibitors	Itraconazole, Erythromycin, Nefazodone, Grapefruit Juice	Pharmacokinetic (CYP3A4 Inhibition); Markedly increases buspirone levels and risk of toxicity.	Avoid combination if possible. If necessary, start buspirone at a very low dose (e.g., 2.5 mg/day) and monitor closely. Avoid large amounts of grapefruit juice.
Potent CYP3A4 Inducers	Rifampin, Carbamazepine, Phenytoin, St. John's Wort	Pharmacokinetic (CYP3A4 Induction); Markedly decreases buspirone levels, leading to loss of efficacy.	Avoid combination if possible. If necessary, monitor for loss of anxiolytic effect and consider increasing the buspirone dose.
Other Serotonergic Agents	SSRIs (Fluoxetine), SNRIs (Venlafaxine), Triptans	Pharmacodynamic; Additive serotonergic effects increase the risk of serotonin syndrome.	Use with caution. Monitor closely for signs and symptoms of serotonin syndrome (agitation, confusion, tachycardia, etc.).
CNS Depressants	Alcohol, Benzodiazepines, Opioids	Pharmacodynamic; Additive CNS depressant effects (drowsiness, dizziness).	Use with caution. Advise patients to avoid alcohol and to be aware of the potential for increased sedation with other CNS depressants.
	23

Section 9: Comparative Analysis: Buspirone in the Anxiolytic Landscape

To fully appreciate the clinical value of buspirone, it must be contextualized within the broader landscape of anxiolytic therapies. Its therapeutic identity is largely defined by its distinct advantages and disadvantages when compared to the two other mainstays of anxiety treatment: benzodiazepines and Selective Serotonin Reuptake Inhibitors (SSRIs). The choice between these agents is not about which is universally "best," but about which is most appropriate for a specific patient profile, reflecting a series of clinical trade-offs.

Buspirone versus Benzodiazepines

The comparison between buspirone and benzodiazepines (e.g., alprazolam, lorazepam, diazepam) represents a fundamental choice between speed of onset and long-term safety.

• Mechanism of Action: They operate on entirely different neurotransmitter systems. Buspirone is a serotonin and dopamine receptor modulator, whereas benzodiazepines are positive allosteric modulators of the GABA-A receptor, enhancing the brain's primary inhibitory signaling.[12]
• Onset of Action: This mechanistic difference leads to a stark contrast in onset. Benzodiazepines provide rapid, often immediate, relief of anxiety symptoms, making them effective for acute anxiety, panic attacks, and situational use.[4] Buspirone has a delayed onset of weeks, rendering it useless for acute situations.[4]
• Side Effect Profile: Benzodiazepines are associated with significant sedation, cognitive slowing, motor impairment, and amnesia. Buspirone's side effect profile is dominated by non-sedating effects like dizziness and nausea, and it is generally better tolerated, especially in the elderly, who are at high risk for falls and cognitive issues with benzodiazepines.[12]
• Dependence and Withdrawal: This is the most critical distinction. Benzodiazepines carry a high risk of physical dependence, tolerance, and abuse, with a potentially severe and dangerous withdrawal syndrome upon discontinuation. Buspirone has a very low risk of dependence and is not associated with a significant withdrawal syndrome, making it a much safer option for long-term, continuous treatment.[4]

The clinical decision between buspirone and a benzodiazepine is therefore a trade-off: a clinician chooses buspirone when the long-term safety from dependence and sedation outweighs the patient's need for immediate anxiolytic relief.

Buspirone versus Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs (e.g., escitalopram, sertraline, fluoxetine) are now considered the first-line pharmacological treatment for GAD and most other anxiety disorders.[3] The comparison with buspirone is one of first-line versus second-line or adjunctive therapy.

• Mechanism of Action: While both ultimately modulate the serotonin system, their mechanisms differ. SSRIs block the reuptake of serotonin, indirectly increasing its synaptic availability, while buspirone is a direct partial agonist at 5-HT1A receptors.[28]
• Spectrum of Efficacy: SSRIs have a much broader spectrum of FDA-approved indications, including major depression, panic disorder, social anxiety disorder, and OCD, in addition to GAD.[29] Buspirone's proven efficacy is largely confined to GAD.
• Side Effect Profile: Both can cause initial GI upset and headaches. However, SSRIs are associated with a significantly higher incidence of sexual dysfunction (e.g., decreased libido, anorgasmia), which can be a major reason for non-adherence. Buspirone has a much lower risk of this side effect and may even be used to treat it.[3] SSRIs also carry a risk of a discontinuation syndrome (withdrawal) if stopped abruptly, a risk that is minimal with buspirone.[41]
• Clinical Role: SSRIs are the established first-line choice for GAD due to their robust evidence base and broad efficacy. Buspirone is typically considered a second-line agent for patients who do not respond to or cannot tolerate SSRIs, or as an adjunctive agent to an SSRI to augment its antidepressant effect or to counteract its sexual side effects.[3]

The choice between buspirone and an SSRI is thus a trade-off between first-line, broad-spectrum efficacy and a potentially more favorable side effect profile for a specific niche.

Defining the Ideal Patient Profile and Clinical Scenarios for Buspirone

Synthesizing these comparisons, the ideal candidate for buspirone monotherapy for GAD is a patient who:

• Has a confirmed diagnosis of GAD without other comorbid anxiety disorders like panic disorder.
• Does not require immediate relief and is capable of adhering to a fixed medication schedule for several weeks before expecting a benefit.
• Has a history of, or significant risk factors for, substance use disorder, making benzodiazepines an unsafe choice.
• Is elderly or otherwise vulnerable to the sedative, cognitive, and motor-impairing effects of benzodiazepines.

As an adjunctive therapy, buspirone is ideal for patients with depression who have had a partial response to an SSRI or for patients with GAD or depression who are experiencing distressing sexual side effects from their primary SSRI treatment.

Feature	Buspirone	Benzodiazepines	Selective Serotonin Reuptake Inhibitors (SSRIs)
Primary Mechanism	5-HT1A Partial Agonist; D2 Antagonist	Positive Allosteric Modulator of GABA-A Receptor	Serotonin (5-HT) Reuptake Inhibition
Onset of Action	Delayed (2–4 weeks)	Rapid (minutes to hours)	Delayed (2–6 weeks)
Risk of Dependence	Very Low	High	Low (Discontinuation Syndrome can occur)
Primary Side Effects	Dizziness, nausea, headache	Sedation, cognitive impairment, amnesia, ataxia	Nausea, insomnia, headache, sexual dysfunction
Sedation	Minimal; similar to placebo	High	Low to Moderate
Sexual Dysfunction	Low risk; may improve SSRI-induced dysfunction	Low risk	High risk
Key Clinical Use	Chronic GAD (especially with substance use risk); SSRI augmentation	Acute anxiety, panic attacks, procedural sedation; short-term use	First-line for GAD, depression, panic disorder, OCD, PTSD; long-term use
	3

Section 10: Conclusion and Expert Recommendations

Buspirone is a unique anxiolytic agent whose clinical value is intrinsically tied to its distinct pharmacological profile. As a non-sedating, non-benzodiazepine anxiolytic with a very low potential for dependence and abuse, it occupies an important and well-defined niche in the treatment of Generalized Anxiety Disorder. Its mechanism as a 5-HT1A partial agonist differentiates it from all other anxiolytic classes, underpinning both its primary therapeutic advantage—a favorable long-term safety profile—and its main clinical limitation—a delayed onset of action. While not a first-line agent for most anxiety disorders, its role as a second-line therapy for GAD, an augmenting agent for depression, and a treatment for SSRI-induced side effects makes it an indispensable tool for the discerning clinician.

Based on the comprehensive analysis of its pharmacology, efficacy, and safety, the following expert recommendations are provided to guide the optimal and safe use of buspirone in clinical practice:

1. Patient Selection is Paramount: The decision to prescribe buspirone should be deliberate and based on a careful assessment of the patient's diagnosis and individual risk factors. Reserve buspirone monotherapy for patients with a confirmed diagnosis of GAD, particularly those for whom the risks of benzodiazepine therapy (e.g., history of substance use, elderly status, need for unimpaired cognition) are unacceptable. The patient must be able to understand and tolerate the delayed onset of action. Consider buspirone as a primary strategy for augmenting antidepressant response in patients with unipolar depression or for managing SSRI-induced sexual dysfunction.
2. Educate to Adhere: Proactive and thorough patient counseling is critical to therapeutic success. Clinicians must explicitly explain the 2- to 4-week delay in therapeutic effect to manage expectations and prevent premature discontinuation. It must be unequivocally stated that buspirone is not a PRN or "rescue" medication and that consistent, daily adherence is required to achieve its benefits.
3. Mandate Comprehensive Interaction Screening: Given the high risk of severe pharmacokinetic interactions, a meticulous medication history is non-negotiable before initiating buspirone. This review must include all prescription and over-the-counter medications, herbal supplements (especially St. John's Wort), and explicit counseling on the interaction with grapefruit juice. The potential for a 19-fold increase in drug exposure with potent CYP3A4 inhibitors underscores the gravity of this step.
4. Dose with Care and Consistency: Adhere to a "start low, go slow" titration strategy to improve tolerability. Begin with 15 mg/day in divided doses and increase by 5 mg every 2-4 days as needed. When co-prescribing with a known potent CYP3A4 inhibitor, initiate buspirone at a substantially reduced dose (e.g., 2.5 mg once or twice daily) and monitor the patient closely. Emphasize to the patient the importance of taking the medication consistently with respect to food intake to ensure stable plasma concentrations.
5. Define Treatment Goals and Reassess: Establish clear treatment goals with the patient at the outset of therapy. Although buspirone has been used safely for extended periods, its efficacy beyond one year has not been systematically established in controlled trials. Therefore, it is prudent to periodically reassess the continued need for the medication and to consider a trial of discontinuation if the patient has been stable and symptom-free for a significant period.

Works cited

1. Buspirone | C21H31N5O2 | CID 2477 - PubChem, accessed August 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Buspirone
2. go.drugbank.com, accessed August 8, 2025, https://go.drugbank.com/drugs/DB00490#:~:text=First%20synthesized%20in%201968%20then,and%20relieve%20symptoms%20of%20anxiety.
3. Buspirone - StatPearls - NCBI Bookshelf, accessed August 8, 2025, https://www.ncbi.nlm.nih.gov/books/NBK531477/
4. en.wikipedia.org, accessed August 8, 2025, https://en.wikipedia.org/wiki/Buspirone
5. What is the mechanism of Buspirone Hydrochloride? - Patsnap Synapse, accessed August 8, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-buspirone-hydrochloride
6. Buspirone (BuSpar): How It Works & Side Effects - Cleveland Clinic, accessed August 8, 2025, https://my.clevelandclinic.org/health/drugs/20084-buspirone-tablets
7. Buspar (buspirone): Side effects, dosage, uses - Medical News Today, accessed August 8, 2025, https://www.medicalnewstoday.com/articles/buspar-side-effects
8. Buspirone: MedlinePlus Drug Information, accessed August 8, 2025, https://medlineplus.gov/druginfo/meds/a688005.html
9. BuSpar Uses, Side Effects, and Dosages - Anxiety - Verywell Mind, accessed August 8, 2025, https://www.verywellmind.com/buspar-treatment-of-social-anxiety-disorder-3024958
10. Buspirone: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 8, 2025, https://go.drugbank.com/drugs/DB00490
11. Definition of Buspirone Hydrochloride - NCI Drug Dictionary, accessed August 8, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/buspirone-hydrochloride
12. Buspirone vs. Xanax - Drugrehab.com, accessed August 8, 2025, https://www.drugrehab.com/addiction/prescription-drugs/xanax/xanax-vs-buspirone/
13. Buspar (Buspirone): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 8, 2025, https://www.rxlist.com/buspar-drug.htm
14. Buspirone: an update on a unique anxiolytic agent - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/3041384/
15. Buspirone free base | CAS# 36505-84-7 | Serotonin Receptor Agonist | MedKoo, accessed August 8, 2025, https://www.medkoo.com/products/30466
16. Buspirone | CAS 36505-84-7 - LGC Standards, accessed August 8, 2025, https://www.lgcstandards.com/ZR/en/Buspirone/p/TRC-B689855
17. buspirone (CHEBI:3223) - EMBL-EBI, accessed August 8, 2025, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3223
18. Buspirone | 36505-84-7 | FB172600 - Biosynth, accessed August 8, 2025, https://www.biosynth.com/p/FB172600/36505-84-7-buspirone
19. Buspirone hydrochloride (B7148) - Product Information Sheet - Sigma-Aldrich, accessed August 8, 2025, https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/152/512/b7148pis.pdf
20. Buspirone hydrochloride - KEGG DRUG - (www.genome.jp)., accessed August 8, 2025, https://www.genome.jp/dbget-bin/www_bget?dr:D00702
21. Showing BioInteractions for Buspirone (DB00490) | DrugBank Online, accessed August 8, 2025, https://go.drugbank.com/drugs/DB00490/biointeractions
22. Generalized Anxiety Disorder (GAD) Recruiting Phase 3 Trials for Buspirone (DB00490), accessed August 8, 2025, https://go.drugbank.com/indications/DBCOND0054747/clinical_trials/DB00490?phase=3&status=recruiting
23. Buspirone: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed August 8, 2025, https://www.medcentral.com/drugs/monograph/8876-388005/buspirone-oral
24. BuSpar (buspirone) dosing, indications, interactions, adverse effects ..., accessed August 8, 2025, https://reference.medscape.com/drug/buspar-buspirone-342913
25. Buspirone oral tablet: Side effects, dosage, uses, and more - Medical News Today, accessed August 8, 2025, https://www.medicalnewstoday.com/articles/drugs-buspirone-oral-tablet
26. Buspirone | National Alliance on Mental Illness (NAMI), accessed August 8, 2025, https://www.nami.org/about-mental-illness/treatments/mental-health-medications/types-of-medication/buspirone/
27. go.drugbank.com, accessed August 8, 2025, https://go.drugbank.com/drugs/DB00490#:~:text=It%20is%20proposed%20that%20buspirone,and%20enhanced%205%2DHT%20release.
28. How effective is BuSpar (buspirone) for anxiety? - SingleCare, accessed August 8, 2025, https://www.singlecare.com/blog/buspar-for-anxiety/
29. Buspirone vs Zoloft: Which is Right for You? - Relevance Recovery, accessed August 8, 2025, https://relevancerecovery.com/blog/buspirone-vs-zoloft/
30. BuSpar - accessdata.fda.gov, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf
31. Buspirone (Orion) 5 mg tablets - NEW ZEALAND DATA SHEET, accessed August 8, 2025, https://www.medsafe.govt.nz/profs/datasheet/b/buspironeoriontab.pdf
32. BuSpar - Drug Summary, accessed August 8, 2025, https://www.pdr.net/drug-summary/Buspirone-Hydrochloride-Tablets--USP--5-mg--10-mg--15-mg--30-mg--buspirone-hydrochloride-1524
33. Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug, accessed August 8, 2025, https://www.semanticscholar.org/paper/Clinical-Pharmacokinetics-and-Pharmacodynamics-of-Mahmood-Sahajwalla/984f0e295c42e9451ea875254cae53b523f47d08
34. Buspirone (oral route) - Side effects & dosage - Mayo Clinic, accessed August 8, 2025, https://www.mayoclinic.org/drugs-supplements/buspirone-oral-route/description/drg-20062457
35. Buspirone in clinical practice - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/2211569/
36. www.ncbi.nlm.nih.gov, accessed August 8, 2025, https://www.ncbi.nlm.nih.gov/books/NBK531477/#:~:text=Buspirone%20is%20primarily%20used%20to,the%20augmentation%20of%20unipolar%20depression.
37. Buspirone - brand name list from Drugs.com, accessed August 8, 2025, https://www.drugs.com/ingredient/buspirone.html
38. Buspirone: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 8, 2025, https://www.rxlist.com/buspirone/generic-drug.htm
39. Buspirone Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 8, 2025, https://www.drugs.com/sfx/buspirone-side-effects.html
40. Review of the side-effect profile of buspirone - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/2870641/
41. Buspar vs. Prozac for Anxiety and Depression: Important Differences and Potential Risks., accessed August 8, 2025, https://www.goodrx.com/compare/buspar-vs-prozac
42. Lexapro vs. Buspar for Anxiety: Important Differences and Potential ..., accessed August 8, 2025, https://www.goodrx.com/compare/lexapro-vs-buspar
43. 12 Buspirone Interactions You Should Know About - Verywell Health, accessed August 8, 2025, https://www.verywellhealth.com/buspirone-interactions-8787418
44. Buspirone vs. Xanax: Which Anxiety Medication Is Right for You? - GoodRx, accessed August 8, 2025, https://www.goodrx.com/health-topic/anxiety-disorders/buspirone-vs-xanax
45. Anxiolytics (anti-anxiety drugs) - Benzodiazepines, buspirone and antidepressants, accessed August 8, 2025, https://video.byui.edu/media/t/1_ch2fzk90
46. What is the comparative efficacy of escitalopram (Selective Serotonin Reuptake Inhibitor - SSRI) versus buspirone (Azapirone) for the treatment of anxiety? - Dr.Oracle, accessed August 8, 2025, https://www.droracle.ai/articles/111810/escitalopram-vs-buspirone-for-anxiety
47. Buspar vs. Zoloft: Side Effects and Differences - RxList, accessed August 8, 2025, https://www.rxlist.com/buspar_vs_zoloft/drugs-condition.htm